Fierce Pharma Sits Down With Adare Pharma Solutions

Sponsored by: Adare Pharma Solutions

It is a time of growth and opportunity for contract development and manufacturing organizations, as pharmaceutical companies of all sizes increasingly rely on trusted and capable partners for drug development.  

And that’s created fertile ground for M&A activity, as well. John Fraher, CEO of Adare Pharma Solutions, recently sat down with Fierce Life Sciences to discuss Adare’s recent acquisition by THL and Frazier Healthcare. New backing means investment, particularly in technology, said Fraher.  

During his conversation with Fierce Life Sciences Head of Conference Programming Zohaib Sheikh, Fraher also explained Adare’s positioning as oral drug delivery continues to gain momentum. Fraher said interest in oral drug delivery aligns with Adare’s expertise in early stage new chemical entity development, and in meeting patient population requirements—such as taste-masking technologies for pediatric and geriatric patients.  

Watch the full interview with Fraher above, and to learn more about Adare Pharma Solutions, visit www.adarepharmasolutions.com


Zohaib Sheikh:

Hi, my name's Zohaib Sheik, head of conference programming for Fierce Life Sciences. And today we're speaking to John Fraher, CEO of Adare Pharma Solutions. Thanks for joining us today, John.

John Fraher:

Welcome, nice to meet you.

Zohaib Sheikh:

So let's jump into things. Recently, you were acquired by THL and Frazier Healthcare. Can you tell us more about the acquisition?

John Fraher:

  We created Adare about five years ago with the support of TPG capital. Since then, we've been building on the legacy success that we've had with predecessor companies, namely Aptalis Pharma Technologies. Now here at the end of this five-year journey, we're now changing ownership with THL and Frazier Healthcare partners. Both of those private equity firms have extensive investments in the healthcare industry, in particular, in the CDMO space. They were very interested in acquiring a new CDMO platform of which to build on, and identified Adare pharmaceuticals as a great opportunity to do so.

John Fraher:

We just completed that transaction in the last couple of weeks, and now look forward to building the organization to much greater heights than we have done with their support that we've done over the past five years.

Zohaib Sheikh:

Can you share with us how this acquisition will shape and change the future of Adare?

John Fraher:

Yes, I think it's going to have a tremendous impact on the future of Adare, the CDMO industry is expanding, and there's tremendous opportunity for growth with continued outsourcing by large, medium and small pharma. I think we are ideally positioned to take advantage of that and continue to provide services to those companies. I think with the backing of THL and Frazier, we now have a committed partner who's willing to invest behind us, willing to invest in new technologies, willing to invest in the global growth of the business.  I would expect that we're going to see significant growth of our company over the next number of years, with the backing of THL and Frazier Healthcare.

Zohaib Sheikh:

You've also changed your name to Adare Pharma Solutions. What does the new name represent and why was this selected?

John Fraher:

Yes, we did. We changed the name for a couple of reasons, and it's really an evolution of the existing names. I think we wanted to identify to our customers that really, we're just changing ownership, nothing was changing. In fact, if anything, we were refocusing our efforts in providing CDMO services to our customers. I think for companies who are looking for new CDMO companies, the addition of the word solutions to the name would make it easier for people to identify who we are and what we do.  We see this as just another evolution in the business and continuing to increase our focus in providing services and solutions to pharmaceutical customers worldwide.

Zohaib Sheikh:

In May 2020, you also acquired Orbis Biosciences. Can you tell us about this acquisition and how this was a good fit?

John Fraher:

Orbis Biosciences is a great company. Good technology, great science, and excellent  scientists and people running that organization. One of the key features of the technology is its unique ability to form very small, homogenous spherical particles going down in size to perhaps 10 microns, allowing those particles to be considered for use in injectable formulations, or slightly larger for incorporation into oral formulations. We are able to take those particles, combine them with the other technologies in the Adare Pharma Solutions tool kit, allowing us to add additional coatings, and put it into different dosage forms. Including the potential to develop sustained-release liquids, for which there's huge demand in the industry. Huge demand for certain patients and certain patient populations.  The integration of Orbis into the Adare family I think is going to bring tremendous benefits, not only to the science that was developed by the Orbis scientists, but also the entire pharma solutions business as a whole, and ultimately our customers and patients who we are servicing every day through the work that we do.

Zohaib Sheikh:

So recently we've seen an increase in activity and innovation and the oral drug delivery space. What do you believe are the drivers and how is Adare positioned to capitalize on this trend?

John Fraher:

It's interesting, the industry over the last number of years has been developing a lot of biologic type products. There's still a very significant portion of the industry requiring the use of small molecules. In the ideal world, every medicine is taken orally, in a pill form or a capsule form. I think that is always one of the goals of the industry, but due to the nature of certain diseases, due to the nature of certain biological solutions, that's just not always feasible. However,  in the oral space, there's still millions of molecules that are being discovered annually. There are many challenges with those molecules, the biggest one being poor insolubility. These drugs are not soluble, so therefore cannot be readily absorbed from the GI tract into the bloodstream. Thus,  there's a need for technologies and capabilities to make that happen.

John Fraher:

 We see the ability for us to continue participating in helping in that part of the industry. In addition, in the later stages of development, really thinking about life cycle management or targeting patient populations, such as pediatrics, geriatrics, patients with dysphasia (Patients with swallowing disorders) There is a continued need to develop dosage forms that are targeted and that are suitable for those patient populations. We have a specialty in that space. We are one of the world's leading taste masking companies for pharmaceutical products, and have developed a range of products globally using our capabilities targeted towards those pediatric and geriatric patients.

John Fraher:

 We see tremendous opportunities continuing in the future, whether that is an early stage of the development cycle looking at NCE, or a later stage of the product life cycle where we are really looking at life cycle management or patient targeting requirements.  We believe that not only with what we do at Adare today, what we brought into the organization with Orbis Biosciences, but now where we're going in the future with the backing of THL and Frazier. We are going to be ideally poised to continue to take advantage and provide solutions for those industry challenges . In addition to that, we are also able to provide our manufacturing capabilities to companies as a source for their manufacturing. Whether that be contract manufacturing, or second source of supply. I think we are ideally leveraged with our capabilities, which includes four high quality GMP facilities in the US and in Europe, to be able to continue to provide those services to partners on a global basis.

Zohaib Sheikh:

Great. Well, I appreciate you taking the time to speak with us today and wish you and Adare continued success.

John Fraher:

Excellent. Thanks for taking an interest in the story. Thanks. Bye-bye.